Literature DB >> 18095109

Expression of the constitutively activated RelA/NF-kappaB in human astrocytic tumors and the in vitro implication in the regulation of urokinase-type plasminogen activator, migration, and invasion.

Keishi Tsunoda1, Gaspar Kitange, Takeo Anda, Hamisi Kimaro Shabani, Makio Kaminogo, Shobu Shibata, Izumi Nagata.   

Abstract

Although malignant gliomas are highly invasive tumors, a characteristic that contributes to the commonly observed therapeutic failures and local disease recurrences, the molecular events that regulate invasion in these tumors remain poorly understood. Because the transcription factor RelA/NF-kappaB has been shown to regulate invasion during several cellular processes, we have examined immunohistochemically expression of the constitutively activated RelA/NF-kappaB in tissues obtained from 49 astrocytic tumors [8 diffuse astrocytomas, 9 anaplastic astrocytomas (AAs) and 32 glioblastomas (GBMs)]. In addition, we examined the in vitro effects of antisense oligonucleotides and curcumin on the expression and activation of RelA/NF-kappaB, urokinase-type plasminogen activator (u-PA) expression, migration, and invasion in the T98G glioma cell line. Expression of the constitutively activated RelA/NF-kappaB was observed in 2 (25%) of 8 cases of diffuse astrocytomas, 5 (55.6%) of 9 cases of AAs, and 30 (93.8%) of 32 cases of GBMs. This expression was significantly correlated with the malignant potential in astrocytic tumors (P < 0.001). Moreover, antisense oligonucleotides and curcumin inhibited phorbol-12-myristate-13-acetate (PMA)-induced RelA/NF-kappaB expression or activation (or both), down-regulated u-PA expression, and reduced the migration and invasive potentials of T98G glioma cells. Thus, the expression of constitutively activated RelA/NF-kappaB is associated with malignancy potential in astrocytic tumors and may play a critical role in the regulation of u-PA expression and invasiveness in gliomas. RelA/NF-kappaB may therefore be an intriguing candidate for studies aimed at understanding and prevention of the invasiveness of gliomas.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 18095109     DOI: 10.1007/s10014-005-0186-1

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  14 in total

1.  NFKBIA deletion in glioblastomas.

Authors:  Markus Bredel; Denise M Scholtens; Ajay K Yadav; Angel A Alvarez; Jaclyn J Renfrow; James P Chandler; Irene L Y Yu; Maria S Carro; Fangping Dai; Michael J Tagge; Roberto Ferrarese; Claudia Bredel; Heidi S Phillips; Paul J Lukac; Pierre A Robe; Astrid Weyerbrock; Hannes Vogel; Steven Dubner; Bret Mobley; Xiaolin He; Adrienne C Scheck; Branimir I Sikic; Kenneth D Aldape; Arnab Chakravarti; Griffith R Harsh
Journal:  N Engl J Med       Date:  2010-12-22       Impact factor: 91.245

2.  Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program.

Authors:  Malcolm A Smith; John M Maris; Richard Gorlick; E Anders Kolb; Richard Lock; Hernan Carol; Stephen T Keir; C Patrick Reynolds; Min H Kang; Christopher L Morton; Jianrong Wu; Peter G Smith; Jie Yu; Peter J Houghton
Journal:  Pediatr Blood Cancer       Date:  2011-10-19       Impact factor: 3.167

3.  Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of sulfasalazine for the treatment of progressing malignant gliomas in adults.

Authors:  Pierre A Robe; Didier H Martin; Minh T Nguyen-Khac; Maria Artesi; Manuel Deprez; Adelin Albert; Sophie Vanbelle; Stephane Califice; Markus Bredel; Vincent Bours
Journal:  BMC Cancer       Date:  2009-10-19       Impact factor: 4.430

4.  Curcumin suppresses colon cancer cell invasion via AMPK-induced inhibition of NF-κB, uPA activator and MMP9.

Authors:  Weihua Tong; Quan Wang; Donghui Sun; Jian Suo
Journal:  Oncol Lett       Date:  2016-09-16       Impact factor: 2.967

5.  Antitumor effect of dehydroxymethylepoxyquinomicin, a small molecule inhibitor of nuclear factor-κB, on glioblastoma.

Authors:  Tsuyoshi Fukushima; Makiko Kawaguchi; Kenji Yorita; Hiroyuki Tanaka; Hideo Takeshima; Kazuo Umezawa; Hiroaki Kataoka
Journal:  Neuro Oncol       Date:  2011-10-03       Impact factor: 12.300

Review 6.  Modulation of glioma risk and progression by dietary nutrients and antiinflammatory agents.

Authors:  Athanassios P Kyritsis; Melissa L Bondy; Victor A Levin
Journal:  Nutr Cancer       Date:  2011       Impact factor: 2.900

7.  PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-κB- and HDAC1-mediated expression and activation of uPA.

Authors:  Zhipeng Zou; Fangyin Zeng; Wanfu Xu; Chunxia Wang; Zhiyong Ke; Q Jane Wang; Fan Deng
Journal:  J Cell Sci       Date:  2012-07-13       Impact factor: 5.285

8.  Influence of caloric restriction on constitutive expression of NF-κB in an experimental mouse astrocytoma.

Authors:  Tiernan J Mulrooney; Jeremy Marsh; Ivan Urits; Thomas N Seyfried; Purna Mukherjee
Journal:  PLoS One       Date:  2011-03-30       Impact factor: 3.240

9.  Identification of non-canonical NF-κB signaling as a critical mediator of Smac mimetic-stimulated migration and invasion of glioblastoma cells.

Authors:  A Tchoghandjian; C Jennewein; I Eckhardt; K Rajalingam; S Fulda
Journal:  Cell Death Dis       Date:  2013-03-28       Impact factor: 8.469

10.  Inhibition of NF- κ B by Dehydroxymethylepoxyquinomicin Suppresses Invasion and Synergistically Potentiates Temozolomide and γ -Radiation Cytotoxicity in Glioblastoma Cells.

Authors:  M S Brassesco; G M Roberto; A G Morales; J C Oliveira; L E A Delsin; J A Pezuk; E T Valera; C G Carlotti; E M Rego; H F de Oliveira; C A Scrideli; K Umezawa; L G Tone
Journal:  Chemother Res Pract       Date:  2013-02-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.